Literature DB >> 6810185

Organomegaly and histopathology in an animal model of mucopolysaccharidosis induced by suramin.

S Rees, G Constantopoulos, J A Barranger, R O Brady.   

Abstract

The trypanocidal drug suramin causes glycosaminoglycan and sphingolipid accumulation in the rat, thus simulating a mucopolysaccharidosis (Constantopoulos et al. 1980). In this paper we report on the extent and nature of the morphological changes that occur in the liver, kidneys, spleen, heart, lung and brain as a result of short or long term suramin administration. The first group of rats received a single intravenous injection of suramin (500 mg/kg) and was sacrificed 3-9 days after the injection. The second group received low doses of suramin (50-90 mg/kg) at 2-3 weekly intervals over 3 months. Samples of the above mentioned organs were processed for light and electronmicroscopy and the remainder of the tissue weighed and assayed for total protein, DNA and RNA content. In both groups of rats, suramin caused an abnormal enlargement of the spleen, kidney, lung and liver, splenomegaly being the most pronounced. The total protein, and DNA content did not alter in the treated rats, however, the RNA content of the spleen increased 100%, 9 days after injection and there was a small but consistent increase in RNA content of the liver, kidney and lung. Significant pathological changes were observed in these organs and also in the brain and heart. The changes were similar in many respects to the pathology seen in the lysosomal storage disorder, mucopolysaccharidosis and further support the proposition that the suramin treated rat might be a useful experimental animal model of the disease. Several mechanisms by which suramin might produce organomegaly in the rat are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810185     DOI: 10.1007/bf00495876

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  11 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Histopathological studies on suramin toxicity in a chimpanzee.

Authors:  D W Gibson; B O Duke; D H Connor
Journal:  Tropenmed Parasitol       Date:  1977-09

4.  Effect of suramin (Bayer 205) on renal ornithine decarboxylase activity and polyamine concentrations in rats.

Authors:  L Selmeci; E Posch; G Simon; L Harsing
Journal:  Biochem Biophys Res Commun       Date:  1979-03-15       Impact factor: 3.575

5.  Chemical aspects of compensatory renal hypertrophy.

Authors:  I W Halliburton; R Y Thomson
Journal:  Cancer Res       Date:  1965-12       Impact factor: 12.701

Review 6.  1,4-Diaminobutane (putrescine), spermidine, and spermine.

Authors:  C W Tabor; H Tabor
Journal:  Annu Rev Biochem       Date:  1976       Impact factor: 23.643

7.  Effect of suramin on the activities of degradative enzymes of sphingolipids in rats.

Authors:  G Constantopoulos; S Rees; B G Cragg; J A Barranger; R O Brady
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-04

8.  Mucopolysaccharidosis in a cat with arylsulfatase B deficiency: a model of Maroteaux-Lamy syndrome.

Authors:  P F Jezyk; M E Haskins; D F Patterson; W J Mellman; M Greenstein
Journal:  Science       Date:  1977-11-25       Impact factor: 47.728

9.  Induction of lysosomal storage by suramin.

Authors:  C H Buys; J M Bouma; M Gruber; E Wisse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-09       Impact factor: 3.000

10.  Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat.

Authors:  G Constantopoulos; S Rees; B G Cragg; J A Barranger; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

View more
  7 in total

1.  Suramin inhibits binding and degradation of platelet-derived growth factor in arterial smooth muscle cells but does not interfere with autocrine stimulation of DNA synthesis.

Authors:  M Sjölund; J Thyberg
Journal:  Cell Tissue Res       Date:  1989-04       Impact factor: 5.249

2.  Suramin-induced storage disease. Mucopolysaccharidosis.

Authors:  G Constantopoulos; S Rees; B G Cragg; J A Barranger; R O Brady
Journal:  Am J Pathol       Date:  1983-11       Impact factor: 4.307

3.  Activation of the high affinity nerve growth factor receptor by two polyanionic chemotherapeutic agents: role in drug induced neurotoxicity.

Authors:  J S Gill; A J Windebank
Journal:  J Neurooncol       Date:  1998-10       Impact factor: 4.130

4.  Purine receptor antagonist modulates serology and affective behaviors in lupus-prone mice: evidence of autoimmune-induced pain?

Authors:  David A Ballok; Boris Sakic
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

5.  On the alcianophilia of the drug suramin used as a tool for inducing experimental mucopolysaccharidosis.

Authors:  B Christensen; R Lüllmann-Rauch
Journal:  Histochemistry       Date:  1988

6.  Nephrotoxicity screening in rats: a validation study.

Authors:  K Fent; E Mayer; G Zbinden
Journal:  Arch Toxicol       Date:  1988-04       Impact factor: 5.153

Review 7.  Pulmonary and generalized lysosomal storage induced by amphiphilic drugs.

Authors:  Z Hruban
Journal:  Environ Health Perspect       Date:  1984-04       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.